Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

CureVac N.V. (CVAC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
7.60-0.10 (-1.30%)
At close: 04:00PM EST
7.51 -0.09 (-1.18%)
After hours: 07:06PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close7.70
Open7.63
Bid7.51 x 800
Ask8.42 x 1000
Day's Range7.53 - 7.73
52 Week Range6.81 - 45.23
Volume327,102
Avg. Volume341,838
Market Cap1.446B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.75
Earnings DateNov 16, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.72
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CVAC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CureVac N.V.
    Analyst Report: CureVac N.V.CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac’s first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company’s other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
    Rating
    Fair Value
    Economic Moat
    8 days agoMorningstar
View more
Advertisement
Advertisement